证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-027 赛隆药业集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 4 月 25 日披露了《2024 年年度报告》，经审计的年度报告数据显示，公司 2024 年度利润总额、净利润、扣除非经常性损益后的净利润三者均为负值，且扣除后 的营业收入低于 3 亿元。根据《深圳证券交易所股票上市规则》第 9.3.1 条规 定，公司股票交易于 2025 年 4 月 28 日被深圳证券交易所实施退市风险警示。若 公司 2025 年度出现《深圳证券交易所股票上市规则》第 9.3.12 条所规定的关于 终止公司股票上市交易的相关情形之一，公司股票将面临被终止上市的风险。 2.公司控股股东、实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与 海南雅亿共赢科技合伙企业（有限合伙）（以下简称"海南雅亿"） 签署了《关 于赛隆药业集团股份有限公司之股份转让协议》（以下简称《 ...

Core Viewpoint - The transfer of 14.16% of shares from the controlling shareholders of Sailong Pharmaceutical to Hainan Yayi will result in a change of control, with Hainan Yayi becoming the new controlling shareholder, although the company will have no actual controller [1][3]. Group 1: Share Transfer and Control Change - The controlling shareholders Cai Nanguai and Tang Lin plan to transfer their shares at a price of 8 yuan per share, totaling 199 million yuan [1]. - After the transfer, Hainan Yayi will hold 24.60% of the voting rights in Sailong Pharmaceutical, making it the controlling shareholder [3]. - Hainan Yayi was established on May 15, 2025, specifically for this transaction and currently has no actual business operations [3]. Group 2: Financial Performance and Risks - Sailong Pharmaceutical has been facing financial difficulties, with only one profitable year since 2020, and has reported losses in other years [4]. - Revenue figures from 2020 to 2024 were 121 million yuan, 247 million yuan, 264 million yuan, 311 million yuan, and 264 million yuan, while net profits were -67.22 million yuan, -23.34 million yuan, -37.31 million yuan, 9.534 million yuan, and -33.1456 million yuan respectively [4]. - The first quarter of 2025 showed a revenue of 54.09 million yuan, a year-on-year decrease of 22.2%, and a net loss of 1.04 million yuan, a decline of 163.9% year-on-year [4]. Group 3: Regulatory and Market Context - Sailong Pharmaceutical's stock was placed under delisting risk warning on April 28, 2025, due to negative profit figures and revenue below 300 million yuan [5]. - The company has outlined strategies to improve its financial situation, including expanding sales channels, increasing marketing efforts, and optimizing internal management [6].

Group 1: Company Announcements - Light Media's controlling shareholder plans to reduce its stake by no more than 29.24 million shares, accounting for up to 1% of the total share capital, to lower debt and improve financial structure [1] - Xinjiang Haoyuan intends to change its name to "Wanqing Energy" and its stock abbreviation accordingly [2] - Xunbang Intelligent plans to acquire controlling shares of Wuxi Indichip Microelectronics, focusing on the automotive chip sector [3] - Kangping Technology intends to acquire 100% of Suolu Electronics for 198 million yuan to enhance core competitiveness [4] - Shentong Express reported April revenue of 4.118 billion yuan, a year-on-year increase of 16.39% [5] - Wenzhou Hongfeng's controlling shareholder plans to reduce its stake by no more than 4.37 million shares, accounting for 1% of total share capital [8] - Changyang Technology plans to invest 29.9 million yuan in Ningbo Huizhixing New Materials [9] - Zhejiang Agricultural Holdings intends to publicly transfer 100% of its subsidiary Huadong Pharmaceutical, valued at 369 million yuan [10] - *ST Jinguang faces delisting risk due to stock price falling below 1 yuan for 10 consecutive trading days [11] - Huibo Yuntong plans to acquire 67.91% of Baode Computer to enhance its competitive edge [12] - Xinhua Group intends to change its name to "Yingxin Development" [13] - Purang Co. plans to reduce its stake by no more than 24,800 shares due to personal funding needs [14] - Xinhecheng plans to participate in a land auction for a commercial plot in Hangzhou, with a starting price of 1.037 billion yuan [15] - *ST Sailong's controlling shareholder plans to transfer 14.16% of shares, potentially changing control [16] - Gaoweida's controlling shareholder plans to reduce its stake by no more than 13.27 million shares due to funding needs [17] - Tianli Lithium Energy's shareholder plans to reduce its stake by no more than 3% [18] - Baijia Qiancheng's shareholder plans to reduce its stake by no more than 9.42 million shares [19] - United Optoelectronics is planning to issue shares to acquire Dongguan Changyi Optoelectronics [20] - Meg Intelligent plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [21] Group 2: Industry Insights - The express delivery industry shows growth, with Shentong Express and Yunda reporting revenue increases of 16.39% and 5.84% respectively in April [5][20] - The automotive chip sector is highlighted as a key investment area, with Xunbang Intelligent's acquisition of Indichip Microelectronics [3] - The energy sector is seeing name changes and strategic shifts, as seen with Xinjiang Haoyuan's rebranding to Wanqing Energy [2] - The pharmaceutical sector is undergoing restructuring, with Zhejiang Agricultural Holdings planning to divest its pharmaceutical subsidiary [10] - The technology sector is active in mergers and acquisitions, with Huibo Yuntong's acquisition of Baode Computer [12]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-026 赛隆药业集团股份有限公司 关于控股股东、实际控制人签署《股份转让协议》 暨公司控制权拟发生变更的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别风险提示： 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司""标的公司"） 控股股东、实际控制人蔡南桂先生、唐霖女士于 2025 年 5 月 18 日与海南雅亿共 赢科技合伙企业（有限合伙）（以下简称"海南雅亿"） 签署了《关于赛隆药 业集团股份有限公司之股份转让协议》（以下简称《股份转让协议》），蔡南桂 先生、唐霖女士拟向海南雅亿转让其持有的公司 14.16%股份（对应的股票数量 为 24,912,205 股，以下简称"标的股份"）。同时，蔡南桂先生、唐霖女士承 诺自本次交易交割日起至其不再持有上市公司股份之日止，无条件且不可撤销地 承诺放弃行使其所持标的公司剩余股份所对应的除收益权和股票处置权之外的 全部股东权利。标的股份作价为人民币 8 元/股 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于赛隆药业集团股份有限公司 2024 年度股东大会的法律意见书 北京市康达律师事务所（以下简称"本所"）接受赛隆药业集团股份有限公司（以 下简称"公司"）委托，指派本所律师对公司 2024 年度股东大会（以下简称"本次会 议""本次股东大会"）的合法性进行见证并出具《北京市康达律师事务所关于赛隆 药业集团股份有限公司 2024 年度股东大会的法律意见书》（以下简称"《法律意见 书》"）。 本所律师根据《中华人民共和国公司 ...

特别提示： 1．本次股东大会无变更、取消、否决议案的情况； 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-025 赛隆药业集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （3）召开方式：以现场投票、网络投票相结合的方式召开。 （4）会议召集人：公司董事会。 （5）会议主持人：董事长蔡南桂。 2．本次股东大会无变更以往股东大会已通过决议的情况。 一、会议召开和出席情况 1．会议召开情况 （1）会议召开时间： 现场会议：2025 年 5 月 16 日（星期五）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 16 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 5 月 16 日 9： 15-15：00。 （2）会议召开地点：珠海市香洲区南湾北路 31 号 2 单元 21 层公司会议室。 （3）公司董事、监事、高级管理人员出席或列席了本次会议 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-024 赛隆药业集团股份有限公司 关于股价异动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 赛隆药业集团股份有限公司（以下简称"公司"或"本公司"），公司股票 （证券简称：*ST 赛隆，证券代码：002898）于 2025 年 4 月 30 日、5 月 6 日、 5 月 7 日收盘价格连续 3 个交易日累计偏离 12.13%，根据深圳证券交易所有关规 定，属于股票异常波动情况。 二、公司关注并核实情况的说明 针对公司股票异常波动，公司对有关事项进行了核查，并向控股股东及实际 控制人核实，不存在应披露而未披露的重大信息，有关情况说明如下： 5.经核查，公司控股股东、实际控制人在股票异动期间不存在买卖公司股票 的行为； 6.经自查，公司不存在违反公平信息披露规定的其他情形。 1.公司前期披露的信息不存在需要更正、补充之处。公司于 2025 年 4 月 25 日披露了《2024 年年度报告》，经审计的年度报告数据显示，公司 2024 年度利 润总额、净利润、扣除非 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-023 注：上表"已质押股份限售和冻结、标记数量"是指质押的高管锁定股；"未质押股份 限售和冻结、标记数量"是指未质押的高管锁定股。 赛隆药业集团股份有限公司 关于公司控股股东部分股份质押延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于近日接到公司控股股东 蔡南桂先生的通知，获悉蔡南桂先生将其持有的本公司部分股份办理了质押延期 手续，具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次质 押延期 | 占其所 | 占公司总 | 是否为 | 是否为 | 质押起 | 原质押 | 延期后质 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 持股份 | | | 补充质 | | | | 质权人 | | | 名称 | 大股东及其 | 数量 | 比例 | 股本比例 | 限售股 | 押 | 始日 | 到期日 | 押 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-022 赛隆药业集团股份有限公司 关于子公司获得注射用伏立康唑药品注册证书的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 赛隆药业集团股份有限公司（以下简称"公司"）全资子公司湖南赛隆药业 （长沙）有限公司于近日获得国家药品监督管理局核准签发的注射用伏立康唑 《药品注册证书》，现将相关情况公告如下： 一、药品基本信息 药品名称：注射用伏立康唑 剂型：注射剂 规格：0.2g 注册分类：化学药品 4 类 证书编号：2025S01166 药品注册标准编号：YBH07852025 药品批准文号：国药准字 H20253998 药品批准文号有效期：至 2030 年 04 月 21 日 二、药品其他相关信息 注射用伏立康唑为《国家基本医疗保险、工伤保险和生育保险药品目录（2 ...

Core Viewpoint - *ST Sailong has faced significant financial challenges, resulting in a stock suspension and a warning of potential delisting due to negative profit indicators and declining revenues [1][6][7]. Financial Performance - In 2024, *ST Sailong reported revenue of 264 million yuan, a year-on-year decrease of 15.15%, and a net loss of 33.146 million yuan, marking a 447.67% decline compared to the previous year [1][4]. - The company’s net profit, excluding non-recurring gains and losses, was also negative at 33.5 million yuan, a staggering decrease of 1275.25% year-on-year [4]. - The gross margin for pharmaceutical products in 2024 was 38.03%, down 8.19% from the previous year [4]. Market Environment - The pharmaceutical industry is experiencing policy changes and intensified competition, leading to a slowdown in overall growth, which has adversely affected *ST Sailong's product sales [2]. - Despite winning bids in national drug procurement, the company has not been able to reverse its declining performance, as the low bidding prices have led to reduced profitability [4][5]. Strategic Response - *ST Sailong plans to continue participating in various procurement initiatives while focusing on expanding market share and sales through cost advantages in its integrated raw material and formulation production [5][9]. - The company aims to explore new market segments, including private hospitals and county-level markets, to seek growth opportunities [9][10]. Historical Context - The company has a history of revising its earnings forecasts, with significant discrepancies noted between initial projections and actual results, leading to regulatory scrutiny [6][7]. - *ST Sailong's revenue has fluctuated between 200 million and 300 million yuan since reaching a peak of 436 million yuan in 2018, with net profits only showing a slight gain in 2023 [1][4]. Future Outlook - The company is focusing on a full industry chain development strategy, prioritizing slow disease medications and exploring high-barrier generics to enhance its competitive edge [10]. - Industry experts suggest that smaller pharmaceutical companies like *ST Sailong may struggle to survive in a market increasingly dominated by larger firms with better economies of scale and cost control [9][10].